Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $256M invested in Adaptimmune Therapeutics in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 15 closing their positions.
206% more call options, than puts
Call options by funds: $379K | Put options by funds: $124K
125% more capital invested
Capital invested by funds: $114M → $256M (+$142M)
2.45% more ownership
Funds ownership: 63.22% → 65.67% (+2.4%)
1% more funds holding
Funds holding: 79 → 80 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$33.1M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$774K |
| 3 |
Millennium Management
New York
|
+$464K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$307K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.81M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.55M |
| 3 |
Morgan Stanley
New York
|
-$1.91M |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$1.69M |
| 5 |
SP
Syncona Portfolio
St Peter Port,
Guernsey
|
-$1.09M |
ADAP Hedge Fund Activity: Q1 2024 in Review
80 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2024, worth a combined $256M — up 125% from $114M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADAP positions and 15 closed out — a net gain of 1 holder — while 17 added to existing stakes and 23 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $33.1M. The largest seller was Citadel Advisors, cutting an estimated $3.81M.
- 80 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2024, up from 79 in Q4 2023.
- Funds reported $256M of Adaptimmune Therapeutics stock for Q1 2024, up 125% quarter-over-quarter.
- 16 funds opened new Adaptimmune Therapeutics positions in Q1 2024 and 15 closed out, a net change of +1 holder.
- The largest Adaptimmune Therapeutics buyer in Q1 2024 was EcoR1 Capital, an estimated $33.1M added.
- The largest Adaptimmune Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $3.81M sold.
Based on aggregated 13F filings for Q1 2024.